Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.

NCT05488821 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors Harboring MAPK Pathway Alterations

Interventions

DRUG: QLH11906

Sponsor

Qilu Pharmaceutical Co., Ltd.